How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

49,632 results for

Hypertension Causes

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

34681. Dose Escalation Study of Pazopanib Plus TH-302

. Liver disease Poorly controlled hypertension [defined as systolic blood pressure (SBP of >140 mmHg or diastolic blood pressure (DBP) of >90 mmHg] NOTE: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. Following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals. At least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP (...) without blood transfusion to maintain hemoglobin level. Adequate liver function as shown by: serum bilirubin ≤ 1.5x ULN PT/PTT/INR ≤ 1.5x ULN ALT and AST ≤ 2.5x ULN Adequate renal function: creatinine clearance (estimated) ≥ 50 cc/min by Cockroft-Gault or 24 hour urine (see Appendix 6). Baseline MUGA or ECHO must demonstrate LVEF ≥ 50% TSH, T3 and T4 within normal limits; Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism. Women of childbearing potential

2011 Clinical Trials

34682. A Trial of Rehabilitation in Obesity Hypoventilation Syndrome (OHS)

of other diseases such as diabetes mellitus and high blood pressure. Currently, the mainstay of treatment is noninvasive ventilation (NIV), this is a mask ventilator that patients use overnight to improve oxygen levels and remove carbon dioxide (the waste gas of breathing), however this does not fully treat the underlying problem. The research group has shown that NIV helps improve activity and contributes to weight loss in this group of patients. The aim of this research will be to investigate (...) ) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Diagnosis of OHS Age >18 BMI > 30 kg/m2 Chronic hypercapnia , daytime PaCO2 >6kPa FEV1/FVC ≥70% Evidence of sleep disordered breathing on overnight studies Tolerated NIV > 4hrs on 1st night during initiation of NIV Exclusion Criteria: Hypercapnic respiratory failure secondary to an identifiable cause other than OHS. Age <18 Respiratory acidosis (pH <7.35) Wheelchair/bedbound patients Cognitive impairment which

2011 Clinical Trials

34683. Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy

of atrial fibrillation, atrial flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de Pointes Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen) Clinically significant resting bradycardia (< 50 beats per minute) Patients who are currently receiving treatment with any medication which has a relative risk of prolonging the QTc (...) proteins stable and active, including many proteins that are involved in tumor growth and death. When Hsp90 is blocked from working, it is believed that many of the other proteins that it stabilizes will also be blocked, which will cause tumor growth to slow or stop. During the study, patients will visit the clinic once a week, every 4 week cycles to receive AUY922 intravenously and to have tests and procedures done. As part of the study, archived tumor tissue will be collected and patients

2011 Clinical Trials

34684. Noninvasive Ventilation in Acute Myocardial Infarction

Inclusion Criteria: acute myocardial infarction with Killip I classification, hemodynamic stability, between 24 and 72 hours post event; agreement to participate in the study, according written informed consent; 45 to 80 years old age. Exclusion Criteria: unstable angina; systolic blood pressure < 80 mmHg; patients who presented ST elevation > 2 mm or with second-degree atrioventricular block; presence of pacemaker. Contacts and Locations Go to Information from the National Library of Medicine To learn (...) Augusto Motta Study Details Study Description Go to Brief Summary: Cardiovascular diseases, especially acute myocardial infarction (AMI), represent the major cause of mortality and morbidity in the world. The myocardial ischemia is often the precipitating cause of pulmonary edema and noninvasive ventilation (NIV) with positive pressure has been used as a therapeutic modality. Objective: to evaluate the effects of NIV on heart rate variability (HRV) and on ventilatory and hemodynamic variables

2011 Clinical Trials

34685. Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

-line chemotherapy with no added therapy Outcome Measures Go to Primary Outcome Measures : Progression free survival [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 36 months ] Hepatic Progression-Free Survival (HPFS) [ Time Frame: date of randomization until the date of first documented progression in the liver according to RECIST 1.1, or detah. ] Eligibility Criteria Go to Information (...) such as bleeding diathesis or coagulopathy that is not correctable by usual therapy of hemostatic agents History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically Presentation of pulmonary insufficiency or clinically evident chronic obstructive pulmonary disease Cirrhosis or portal hypertension Prior external beam radiation treatment to the liver Prior intra-arterial liver directed therapy, including transcatheter arterial

2011 Clinical Trials

34686. Assessment of Nutritional Consequences of Sleeve Gastrectomy

deficiencies in patients undergoing a longitudinal sleeve gastrectomy for morbid obesity Outcome Measures Go to Primary Outcome Measures : micro nutritional status of patients undergoing sleeve gastrectomy [ Time Frame: at 3, 6, 12, 18 and 24 months after intervention ] Secondary Outcome Measures : physical composition measured by impedancemetry [ Time Frame: at 3, 6, 12, 18 and 24 months ] arterial blood pressure [ Time Frame: at 3, 6, 12, 18 and 24 months ] HOMA test [ Time Frame: at 3, 6, 12, 18 and 24 (...) , and gastric bypass (GBP), an irreversible procedure, which associates restriction and mild malabsorption. Longitudinal sleeve gastrectomy (LSG) is another bariatric procedure which tends to develop quickly. More recent, this technique is recognized in France by the High Authority of Health since 2008, consisting of fundus and greater curvature resection, removing 75 % the gastric volume, leaving a narrow gastric tube or "sleeve". Although malabsorption does not occur in most bariatric procedures

2011 Clinical Trials

34687. Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

; AST and/or ALT > 3 times the upper limit of normal or any other clinically significant lab abnormality which in the opinion of the investigator should be exclusionary Uncontrolled hypertension as defined as sustained systolic blood pressure (SBP) > 200 mmHg or diastolic BP (DBP) > 110 mmHg at Screening Patients with a recent history (< 5 years) of or new screening finding of malignant neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if excised and no evidence (...) diabetes Other pain more severe than neuropathic pain Progressive or degenerative neurological disorder Myopathy Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's disease) Active infection Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis) Positive HIV or HTLV at Screening Active Hepatitis B or C as determined by Hepatitis B core antibody (HBcAB), antibody to Hepatitis B antigen (IgG and IgM; HbsAb), Hepatitis B surface antigen (HBsAg

2011 Clinical Trials

34688. Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)

the evaluation of cognitive function, including abuse of alcohol, or DSM-IV diagnosed abuse of drugs or mental drugs in past 5 years. Severe anemia patients should also be excluded. With severe mental dysfunction, e.g. hemiplegia, aphasia, visually and hearing impairment, etc. With cardiac disorder, e.g. heart rate ≦ 50 or ≧ 180 times/minute With supine or sitting Systolic blood pressure ≦ 100 or ≧ 180 mmHg With other disease, especially hepatic, renal, or cardiac disorders, e.g. ALT/SGPT or AST/SGOT > 3 (...) criteria of vascular dementia according to National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) With Mini-Mental State Examination (MMSE score) ≦17 (illiteracy); ≦20 (elementary school); ≦24 (high school or above) With Hachinski's ischemic score (HIS) ≧7 With marrow-sea deficiency from Chinese medicine's perspective Classified mild to moderate dementia based on MMSE score With body weight 45 to 95 Kg Aged

2011 Clinical Trials

34689. How Has Glaucoma Affected Your Quality of Life?

Description Go to Brief Summary: Hypothesis 1: Self-reported health-related quality of life decreases as vision impairment worsens in subjects with glaucoma. Hypothesis 2: Changes in health-related quality of life are associated with changes in clinical measures of vision and performance-based measures of visual function. Condition or disease Glaucoma Quality of Life Detailed Description: You are being asked to participate in this research study because you have glaucoma, which is the second leading cause (...) of blindness in the world and accounts for 15% of blindness worldwide. Vision loss caused by glaucoma can significantly worsen your health-related quality of life. Despite the fact that glaucoma has such a big impact on a large number of people, research examining the long-term effects of glaucoma-related vision loss on one's quality of life is scarce. The purpose of this study is to look at the long-term effect of this condition on your quality of life so that we may gain valuable information about what

2011 Clinical Trials

34690. Orthogonal Polarisation Study in Young, Elderly and Type 2 Diabetics

): Maastricht University Medical Center Study Details Study Description Go to Brief Summary: Aging is accompanied by a progressive loss of skeletal muscle mass and strength, leading to the loss of functional capacity and an increased risk of developing chronic metabolic disease. One of these metabolic diseases interacting with muscle mass is Diabetes Mellitus type 2. Diabetes Mellitus type 2 is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. It has (...) Eligible for Study: Male Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Male Aged between 20-30 or 65-80 years BMI < 30 kg/m2 Non insulin-dependent Diabetes mellitus type 2 patients. Use of oral anti-diabetic agents (TZD's, Metformin and/or a sulfonylurea derivative) is allowed. Exclusion Criteria: Positive history for hypertension Smoking Hypertension (according to WHO criteria)18 Use of medication, except for oral blood glucose lowering medication All co morbidities interacting

2011 Clinical Trials

34691. A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes); visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR, such as evidence of new optic disc cupping, evidence of new visual field defects, intraocular pressure (IOP) > 24mmHg. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your (...) inhibitor Additional relevant MeSH terms: Layout table for MeSH terms Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Trametinib Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

2011 Clinical Trials

34692. Improved Patient Recovery After Anesthesia

Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: adult ASA class I-III subjects of both genders scheduled to undergo eye surgery at the Moran Hospital. Exclusion Criteria: a history of renal or hepatic disease, chronic alcohol or drug abuse, disabling neuropsychiatric disorder, hypersensitivity, or unusual response to other halogenated anesthetics, pulmonary hypertension, increased intracranial pressure, seizure disorder (...) recovered from anesthesia faster because the treatment (inspired CO2) caused them to breath more vigorously or because the treatment caused the anesthetic vapors to be cleared more rapidly from the brain. Our new application uses essentially the same study protocol as the former study but adds chest bands to measure the patient's rate of breathing and expired gas monitoring to measure the rate at which the vapors are removed. Study Design Go to Layout table for study information Study Type

2011 Clinical Trials

34693. The Effect of Hyperbilirubinemia on CV Disease, Neurocog Function and Renal Function

Information provided by (Responsible Party): St Stephens Aids Trust Study Details Study Description Go to Brief Summary: Use of some protease inhibitors is associated with elevations of a blood pigment called bilirubin. This may occasionally lead to yellowing of the eyes (scleral icterus) or jaundice, but in the general population bilirubin elevations have been shown to have antioxidant and anti-inflammatory properties that could be associated with reduced risk of cardiovascular or other disease events (...) enzyme. Elevated levels of unconjugated bilirubin are best characterized among individuals with Gilbert syndrome, which is the most common inherited cause of unconjugated hyperbilirubinemia, present in 3-10% of the general population. Gilbert syndrome arises through variants in the UGT1A1 enzyme, thus these PIs induce a biochemical picture similar to Gilbert syndrome. Although elevations of bilirubin may occasionally lead to scleral icterus or jaundice, cohort studies of individuals with Gilbert

2011 Clinical Trials

34694. MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

[ Time Frame: Predose on Day 1 of every treatment cycle; end of treatment; Days 30, 60 and 90 post treatment; every 3 months post treatrment till end of study (approximately 15 months) ] Participants with positive ADA to MEDI-573 are reported in the below table. This outcome was not evaluated for Phase 2 as it was not launched by the sponsor due to strategic business reasons. Phase 2: Best Overall Tumor Response [ Time Frame: From Day 1 until disease progression or death due to any cause, whichever (...) occurred first (approximately 15 months) ] Phase 2 part of the study was not launched by the sponsor due to strategic business reasons. Therefore, this outcome was not evaluated. Phase 2: Objective Response Rate [ Time Frame: From Day 1 until disease progression or death due to any cause, whichever occurred first (approximately 15 months) ] Phase 2 part of the study was not launched by the sponsor due to strategic business reasons. Therefore, this outcome was not evaluated. Phase 2: Progression-free

2011 Clinical Trials

34695. Improving Oral Care to Reduce Hospital-Acquired Pneumonia (HAP) in the Acute Neurologically Impaired Adult

Acquired Pneumonia Occurrences [ Time Frame: 10 months ] Hospital acquired pneumonia is acquired greater than 48 hours after admission and is diagnosed by a positive chest x-ray plus 2 of the following 3 symptoms: presence of fever, elevated serum white blood cells count, and positive sputum specimen. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about (...) Pneumonia Other: Enhanced oral care protocol Not Applicable Detailed Description: Overview Problem: Hospital-acquired pneumonia (HAP) is the second most common nosocomial infection and is a significant cause of morbidity and mortality. In the surgical population, HAP is associated with a 55% increase in length of stay and increased costs of approximately $31,000.00 per case. Neurologically impaired patients (those with brain injury causing alterations in mental status, immobility, impaired swallowing

2011 Clinical Trials

34696. Phase I/II

by the presence of 15-29% blasts in peripheral blood (PB) or bone marrow (BM), >/= 20% basophils in PB or BM, >/= 30% blasts plus promyelocytes (with blasts <30%) in PB or BM, <100 x10(9)/L platelets unrelated to therapy, or by clonal cytogenetics evolution (i.e., the presence of cytogenetic abnormalities other than the Philadelphia chromosome); CML-BP is defined by the presence of >/= 30% blasts in the bone marrow and/or peripheral blood or the presence of extramedullary disease. Patients are eligible (...) : Uncontrolled angina within 3 months. Diagnosed or suspected congenital long QT syndrome; Any history of clinically significant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsades de pointes); Prolonged QTc interval on pre-entry electrocardiogram (> 470 msec) on the Fridericia's correction; Uncontrolled hypertension (defined for this protocol as sustained systolic BP >/=150 and diastolic >/=100); Patients currently taking drugs that are generally accepted to have

2011 Clinical Trials

34697. The Bolus Dose of Dexmedetomidine (ED50) That Avoids Hemodynamic Compromise in Children

quickly. However, this is often infeasible and usually inconvenient. The investigators aim to determine the dose of dexmedetomidine that can be given rapidly (over 5 seconds) without causing significant changes in heart rate and blood pressure. This will be the only study specific intervention. Condition or disease Intervention/treatment Phase Hemodynamic Instability Drug: Dexmedetomidine Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial (...) Columbia Information provided by (Responsible Party): Carolyne Montgomery, University of British Columbia Study Details Study Description Go to Brief Summary: Dexmedetomidine is a sedative drug that has many benefits when given to children under anesthesia, such as improved pain relief and reduced agitation following their surgery. It is usually given as an intravenous infusion over 10 minutes, to avoid the changes in heart rate and blood pressure that are occasionally seen when it is administered more

2011 Clinical Trials

34698. Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

cardiovascular disease, defined as any of the following conditions: i. Uncontrolled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg) ii. Prior history of hypertensive crisis or hypertensive encephalopathy iii. Myocardial infarction within 6 months iv. Unstable angina v. New York heart association grade II or greater congestive heart failure (Appendix C) vi. Serious cardiac arrhythmia requiring medication vii. LVEF < 50% or below institutional limit (...) in combination with MEK inhibitor cobimetinib; or, (2) SOC plus bevacizumab, an anti-VEGF antibody that suppresses new blood vessel formation and can stimulate the immune system. Previous clinical studies in melanoma have shown that bevacizumab may improve clinical benefit (progression free survival) if combined with ipilimumab or abraxane. Preclinical studies suggest that VEGF increase plays a role in resistance to BRAF inhibitors. This randomized study will ask whether the addition of bevacizumab

2011 Clinical Trials

34699. A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

transplant or who are awaiting a heart transplant Subjects with systolic blood pressure >160 mmHg or diastolic blood pressure >90 mmHg while on anti-hypertensive treatment General Health: Subjects with end stage renal disease requiring renal replacement therapy Subjects receiving drug therapy to treat liver disease Subjects with diagnosis of cancer ( other than superficial squamous. basal cell skin cancer or adequately treated cervical carcinoma in situ) in the past 3 years or who are currently receiving (...) of elevated triglycerides, low high-density lipoprotein cholesterol (HDL-C), and small low-density lipoprotein cholesterol (LDL-C) particles, is commonly found in individuals with T2D. In diabetic patients, the LDL particles tend to be smaller, denser, and more atherogenic than in the general population. As a result, in patients with diabetes, lowering LDL-C levels may lead to a greater benefit in terms of Cardiovascular disease (CVD) risk reduction than in patients without diabetes. Multiple clinical

2011 Clinical Trials

34700. Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

) could improve pulmonary hypertension and therefore exercise tolerance in COPD. Unfortunately the use of non-selective pulmonary vasodilator therapy in oral, intravenous or subcutaneous form for PAH patients who have unrelated concomitant COPD, is known to cause worsening gas exchange and intensification of symptoms despite a decrease in pulmonary vascular resistance and arterial pressures. We hypothesize that an inhaled pulmonary vasodilator may not worsen ventilation-perfusion mismatching (...) , 2015 Sponsor: University of Florida Collaborator: United Therapeutics Information provided by (Responsible Party): University of Florida Study Details Study Description Go to Brief Summary: The purpose of this study is to see how inhaled treprostinil sodium (Tyvaso) affects the amount of air and blood that reach the alveoli, or tiy air sacs, in the lungs of patients with Group 1 Pulmonary Arterial Hypertension with concomitant Chronic Obstructive Pulmonary Disease (COPD). Condition or disease

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>